Tokyo, Japan and Cambridge and London, UK — September 29, 2025 — Leads & Copy — Nxera Pharma Co., Ltd. (TSE 4565) announced it has achieved a second R&D milestone in its collaboration with AbbVie, focused on neurological diseases. This achievement triggers a US$10 million payment to Nxera.
The collaboration, initiated in 2022, leverages Nxera’s NxWave™ platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease. The milestone is related to the identification of validated and differentiated ‘hit’ molecules against a neurology target.
Under the agreement, Nxera is eligible to receive up to US$40 million in near-term research milestones, and further potential option, development, and commercial milestones totaling up to US$1.2 billion, plus tiered royalties on global sales. This is the second milestone received in this collaboration, following the first milestone which was achieved in June 2024.
Dr. Matt Barnes, Chief Scientific Officer and President of Nxera Pharma UK, stated that this milestone highlights the productivity of their collaboration with AbbVie and the remarkable work of their teams. He added that they are proud of the progress achieved and look forward to continuing their work towards impactful new therapies for patients.
The milestone payment will be recognized in the third quarter of 2025.
Contact:
Shinya Tsuzuki, VP, Head of Investor Relations
Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures
Maya Bennison, Communications Manager
+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@Nxera.life
MEDiSTRAVA (for International Media)
Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 | Nxera@medistrava.com
Source: Nxera Pharma
